首页>
外国专利>
Ex-vivo prognosis of aggressive endocrine tumor of patient comprises determining marker gene expression profile of assayed endocrine tumor aggressiveness, or peptide marker, and comparing the expression profile and deducing
Ex-vivo prognosis of aggressive endocrine tumor of patient comprises determining marker gene expression profile of assayed endocrine tumor aggressiveness, or peptide marker, and comparing the expression profile and deducing
Ex-vivo prognosis of an aggressive endocrine tumor of a patient comprises: determining marker gene expression profile of assayed endocrine tumor aggressiveness, or a peptide marker for which the marker gene encodes, or which corresponds to a protein comprising peptide sequence code for which the marker gene encodes, from a biological sample of the patient; and comparing the expression profile obtained in a reference profile and deducing if the identified tumor is an aggressive tumor or non-aggressive tumor. Method of ex-vivo prognosis of an aggressive endocrine tumor of a patient comprises: determining marker gene expression profile of assayed endocrine tumor aggressiveness, or a peptide marker for which the marker gene encodes, or which corresponds to a protein comprising peptide sequence code for which the marker gene encodes, where the marker gene comprises sequences comprising SEQ ID NO:1 (DCAMKL3) (atgatgtgttttgcttcccctttgtaacca), SEQ ID NO: 2 (ADAMTS6) (gatgctggaagaggagggcagtcagtgtca), SEQ ID NO: 3 (AURKB) (cgggtgcgtgtgtttgtatgtctgtgtatg), SEQ ID NO: 4 (CENPE) (agtctttaccatcacctcatccagttcgct), SEQ ID NO: 5 (PITXI) (aactcgggcctcaacaacatcaacaacctc), or SEQ ID NO: 6 (PITXII) (gtctcctcatcttcctgtcaccatccccag), from a biological sample of the patient; and comparing the expression profile obtained in a reference profile and deducing if the identified tumor is an aggressive tumor or non-aggressive tumor. An independent claim is included for a diagnostic kit for endocrine tumors in the biological sample comprising means for the detection in biological sample and determining the expression profile of the marker gene of assayed endocrine tumor aggressiveness, or the marker peptide for which the marker gene encodes, or which corresponds to protein comprising the peptide sequence for which the marker gene codes, and instructions to correlate the detection of the optional presence of a hypophyseal tumor and to determine whether the identified tumor is aggressive or non aggressive tumor.
展开▼
机译：患者的侵袭性内分泌肿瘤的离体预后包括：确定测定的内分泌肿瘤侵袭性的标记物基因表达谱，或该标记物基因编码的肽标记物，或对应于包含该标记物的肽序列代码的蛋白质基因编码自患者的生物学样品;比较在参考谱中获得的表达谱，并推论所鉴定的肿瘤是侵袭性肿瘤还是非侵袭性肿瘤。患者的侵袭性内分泌肿瘤的离体预后方法包括：确定测定的内分泌肿瘤侵袭性的标志物基因表达谱，或该标志物基因编码的肽标志物，或对应于包含其肽序列编码的蛋白质的蛋白，标记基因编码，其中标记基因包含的序列包含SEQ ID NO：1（DCAMKL3）（atgatgtgtttttgcttcccctttgtaacca），SEQ ID NO：2（ADAMTS6）（gatgctggaagaggagggcagtcagtgtca），SEQ ID NO：3（AURKB）（cgggtggtgt>编号：4（CENPE）（agtctttaccatcacctcatccagttcgct），SEQ ID NO：5（PITXI）（aactcgggcctcaacaacatcaacaacctc）或SEQ ID NO：6（PITXII）（gtctcctcatcttcctgtcaccatccccag）;比较在参考谱中获得的表达谱，并推论所鉴定的肿瘤是侵袭性肿瘤还是非侵袭性肿瘤。包括针对生物样品中内分泌肿瘤的诊断试剂盒的独立权利要求，该试剂盒包括用于在生物样品中进行检测并确定测定的内分泌肿瘤侵袭性的标志物基因或标志物基因编码的标志物肽的表达特征的装置，或相应于包含标记基因编码的肽序列的蛋白质的蛋白质，以及与关联检测是否存在下垂体肿瘤并确定所鉴定的肿瘤是侵袭性肿瘤还是非侵袭性肿瘤的指令。
展开▼
